Average Co-Inventor Count = 3.45
ph-index = 9
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Boehringer Ingelheim International Gmbh (14 from 1,536 patents)
2. Ajinomoto Co., Ltd. (2 from 1,929 patents)
3. Neurosearch A/s (1 from 206 patents)
4. Boehringer Ingelheim Pharma Gmbh & Co Kg (194 patents)
16 patents:
1. 12312352 - Use of a DPP-4 inhibitor in SIRS and/or sepsis
2. 11291668 - Uses of DPP IV inhibitors
3. 10092571 - Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
4. 10080754 - Uses of DPP IV inhibitors
5. 10034877 - Treatment for diabetes in patients inappropriate for metformin therapy
6. 9486526 - Treatment for diabetes in patients inappropriate for metformin therapy
7. 9457029 - Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
8. 9173859 - Uses of DPP IV inhibitors
9. 8853156 - Treatment for diabetes in patients inappropriate for metformin therapy
10. 8846695 - Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
11. 8673927 - Uses of DPP-IV inhibitors
12. 8551957 - Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
13. 8232281 - Uses of DPP-IV inhibitors
14. 8202884 - Treatment of type 2 diabetes
15. 7838500 - Crystalline form of 1'-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments